Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, FENNEC PHARMACEUTICALS INC. reported revenue of $45M, down 6.1% year over year. Operating margin was -14.1% and net margin -21.8%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from FENC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $45M | -14.1% | -21.8% |
| FY2024 | $48M | 5.4% | -0.9% |
| FY2023 | $21M | -60.1% | -75.5% |
| FY2022 | $2M | -1471.6% | -1544.9% |
| FY2021 | n/a | n/a | n/a |
How does FENC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.